ArticleCureus2026
The Prophylactic Role of Tranexamic Acid in Reducing Blood Loss During Cesarean Delivery: A Prospective Randomized Controlled Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostpartum hemorrhage (PPH) is a major risk associated with cesarean delivery. This randomized controlled trial (RCT) aimed to evaluate the prophylactic role of intravenous tranexamic acid (TXA) in reducing total intraoperative blood loss in women undergoing lower-segment cesarean section (LSCS). MATERIALS AND
methodsThe study was conducted at the Autonomous State Medical College, Fatehpur, from September 1, 2024, to March 31, 2025. The primary aim of the trial was to investigate the effect of TXA on perioperative and postoperative blood loss during cesarean section in a low-resource setting. A simple randomization technique was used to allocate 300 participants to either group in a 1:1 ratio.
resultsThe median estimated blood loss (EBL) was identical in both groups at 450 mL (IQR, 250-1000 mL), as measured by the gravimetric method. The mean EBL was lower in the TXA group (460.33 mL) than in the placebo group (511.93 mL) (p < 0.05). The mean changes in hemoglobin level and packed cell volume (PCV) were similar between the two groups. There was no statistically significant difference between the groups in the need for additional uterotonics (misoprostol, carboprost, or carbetocin). Blood transfusions were required in 4.7% (7 cases) of the TXA group and 9.3% (14 cases) of the placebo group. Gastrointestinal side effects were reported in 42.0% of the TXA group and 37.3% of the placebo group. No thromboembolic events were reported in either group. The mean birth weight and mean APGAR scores at one minute were comparable between the two groups.
conclusionThis study supports the prophylactic use of TXA during cesarean delivery to reduce intraoperative blood loss. The significant reduction in mean EBL, combined with the absence of major adverse effects, underscores the role of TXA as a safe and effective adjunct to standard uterotonic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.